© www.istockphoto.com/Firstsignal

University of Sheffield spinout gets £5m for gene therapies targeting ALS and FTD, advancing towards clinical trials.

©NicoElNino - stock.adobe.com

Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.

© manfredrichter - pixabay.com

Austrian Kern Tec GmbH has raised €12m in the biggest Series A  financing ever seen for a foodtech company in Austria to scale food production from waste.

Picture: © Cavan Images / Westend61

Austria has gained an outstanding reputation as a research location in the field of life sciences both as a vibrant hub for science and as a cluster for research-oriented and manufacturing companies. The ABA links international companies with this ecosystem

© BenevolentAI Ltd

British drug discovery specialist BenevolentAI Ltd has licenced its end-to-end AI platform capabilities to Merck KGaA to deliver novel drug candidates for three targets in oncology, neurology and immunology.
 

Anti-CD45RC Abs suppresses the acute immune response by causing the death of harmful CD45RC+ T cells driving (severe) disease in patients. © Aborleris Pharma SA (Zoersel, Nantes

Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.

© Shutterbug75 - pixabay.com

The Cultivated B ist the first company in the world to apply for EU-Novel-Food authorisation of a hotdog made from plant protein and cultivated muscle cells.

Diagram of a normal brain compared to the brain of a person with Alzheimer's. © Garrondo - wikipedia.org

A Belgian-British research team has identified the human protein underlying necroptosis of human brain cells in Alzheimer’s mice and stopped cell death.

Centre de R&D Pierre Fabre, Oncopole, Toulouse
© Don-vip - wikipedia.org

French pharma company Pierre Fabre Laboratories has baged Vertical Bio to push development of the company’s NSCLC candidate.

C

© BioLamina AB

French-US-based investment specialist Lauxera Capital Partners announced today that it has invested €17m in Swedish cell culture company BioLamina AB (BioLamina)